F5
Hematologic System · Coagulation, Fibrin Formation & Fibrinolysis
Is every F5 variant factor V Leiden?
F5 encodes clotting factor V, which helps the body form clots after injury. Factor V Leiden refers to a particular variant, so other F5 findings cannot automatically be given the same interpretation.
- Common Gene Name
- coagulation factor V
- NCBI Gene ID
- 2153
- Chromosome
- 1
Clinical Evidence Status
Actionability report availableEstablished disease relationshipTumor or drug-label biomarker context
These labels describe available evidence about a gene. They do not classify your variant or recommend a treatment.
Answer Sources
Explore supporting evidence (12 records)
| Condition or drug | Evidence | Grade / status | Context | Source |
|---|---|---|---|---|
| thrombophilia due to activated protein C resistance | ClinGen gene-disease validity | Definitive | Autosomal dominant | View source 2019-09-30 |
| congenital factor V deficiency | ClinGen gene-disease validity | Definitive | Autosomal recessive | View source 2020-03-25 |
| Factor V Leiden thrombophilia | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2023-08 | |
| Factor V deficiency | MedlinePlus related condition | Association type varies; no grade assigned here | View source 2023-08 | |
| Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A) | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2022-11-21 |
| F5: Factor V deficiency (AR) | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2024-03-24 |
| Factor V Leiden, Heterozygous | ClinGen clinical actionability | Scored report; not a validity grade | Adult | View source 2024-03-24 |
| Avatrombopag (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Hematology | View source |
| Eltrombopag (1) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Hematology | View source |
| Lusutrombopag (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Hematology | View source |
| Rivaroxaban | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Cardiology | View source |
| Tamoxifen (2) | FDA labeling biomarker | Label mentions biomarker; actionability not inferred | Oncology | View source |
Source snapshot: 2026-09-09. Consumer text updated: 2026-09-10. Source dates describe the cited records, not a new clinical review.
← Back to Hematologic System